Literature DB >> 7948516

Bilateral pulmonary infiltrates in association with disseminated actinomycosis.

F Dontfraid1, R Ramphal.   

Abstract

The most common infectious cause of bilateral upper-lobe pulmonary disease is tuberculosis. However, we recently encountered a patient with bilateral apical infiltrates and multiple soft-tissue abscesses caused by Actinomyces odontolyticus. Other findings included fever, weight loss, and leukocytosis, and the patient's only known source of immunosuppression was a long history of alcoholism. There was no history of diabetes, steroid use, or other chronic underlying disease. The diagnosis was made by culture of drainage fluid from one abscess. Therapy with intravenous penicillin G led to rapid clinical improvement and reduction in the infiltrates. To our knowledge, the presentation of pulmonary infection, with bilateral apical infiltrates due to A. odontolyticus has not been previously reported in the medical literature.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7948516     DOI: 10.1093/clinids/19.1.143

Source DB:  PubMed          Journal:  Clin Infect Dis        ISSN: 1058-4838            Impact factor:   9.079


  3 in total

1.  Actinomyces odontolyticus bacteraemia associated with cervical and mediastinal abscesses in an immunocompetent patient: First reported case in Qatar.

Authors:  Almurtada Razok; Maisa Ali; Loai Aker; Hisham Ziglam
Journal:  New Microbes New Infect       Date:  2022-01-17

2.  A 5-year retrospective study of Actinomyces odontolyticus bacteremia in the state of Qatar, case series.

Authors:  Maisa Ali; Almurtada Razok; Hisham Ziglam
Journal:  Ann Med Surg (Lond)       Date:  2022-04-02

3.  Drastically progressive lung cavity lesion caused by Actinomyces odontolyticus in a patient undergoing chemoradiotherapy: A case report and literature review.

Authors:  Takeshi Matsumoto; Yusuke Kusakabe; Masamitsu Enomoto; Naoki Yamamoto; Kensaku Aihara; Shinpachi Yamaoka; Michiaki Mishima
Journal:  Respir Med Case Rep       Date:  2019-10-14
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.